Marc Schwartz, MD
Cardiovascular Disease · Bryan, TXNPI 1275505570
Payments from drug & device makers
Across 777 payments — averaging $13.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$902
- Amarin Pharma, Inc.$520
- Pfizer$417
- plus $4K from 32 others
What the payments were for
- Food & beverage$10,472100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 272 | $2,232 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 70 | $1,463 |
| Novartis | 77 | $1,080 |
| E.r. Squibb & Sons, L.L.C. | 94 | $902 |
| Amarin Pharma, Inc. | 70 | $520 |
| Pfizer | 29 | $417 |
| Merck | 26 | $402 |
| Baxter Healthcare | 11 | $387 |
| Abiomed | 4 | $319 |
| Johnson & Johnson | 13 | $280 |
| Boston Scientific | 6 | $265 |
| Esperion Therapeutics, Inc. | 12 | $233 |
| Abbott | 5 | $233 |
| AstraZeneca | 9 | $214 |
| Sanofi-aventis U.S. LLC | 14 | $198 |
| Alnylam Pharmaceuticals Inc. | 6 | $177 |
| Kestra Medical Technology Services, Inc. | 3 | $177 |
| Medtronic(2 entities) | 8 | $145 |
| Boehringer Ingelheim | 6 | $106 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $99 |
| Irhythm Technologies, Inc. | 5 | $92 |
| Novo Nordisk | 5 | $90 |
| Regeneron Healthcare Solutions, Inc. | 6 | $84 |
| Lexicon Pharmaceuticals, Inc. | 3 | $70 |
| Amryt Pharma Holdings Ltd | 2 | $46 |
| Atricure, Inc. | 1 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Cardiva Medical, Inc. | 1 | $21 |
| Cvrx, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
| CMP Pharma, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
| Agepha Pharma FZ LLC | 1 | $14 |
| Avinger Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$260
- ENTRESTO$130
- Watchman$123
- CAMZYOS$123
- XARELTO$122
- Assure WCD$117
- Repatha$116
- Mitra Clip system$113
- NEXLIZET$104
- NEXLETOL$104
How this compares
$10,505 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 599 | $615,778 |
| VascepaIcosapent Ethyl | 600 | $414,029 |
| EntrestoSacubitril/Valsartan | 310 | $324,655 |
| Repatha SureclickEvolocumab | 255 | $213,771 |
| JardianceEmpagliflozin | 202 | $197,710 |
| FarxigaDapagliflozin Propanediol | 116 | $92,326 |
| MultaqDronedarone Hcl | 59 | $83,306 |
| XareltoRivaroxaban | 57 | $53,464 |
| Praluent PenAlirocumab | 34 | $39,256 |
| NexlizetBempedoic Acid/Ezetimibe | 46 | $34,602 |
| EdarbiAzilsartan Medoxomil | 57 | $30,632 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 49 | $21,879 |
| Icosapent Ethyl | 56 | $18,928 |
| NexletolBempedoic Acid | 20 | $17,704 |
| Metoprolol Succinate | 743 | $15,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $417 | $615,778599 claims |
| NovartisEntresto | $1,080 | $324,655310 claims |
| Boehringer IngelheimJardiance | $106 | $197,710202 claims |
| AstraZenecaFarxiga | $214 | $92,326116 claims |
| Sanofi-aventis U.S. LLCMultaq | $198 | $83,30659 claims |
| Johnson & JohnsonXarelto | $280 | $53,46457 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $233 | $52,30666 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $25 | $9,73717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Bryan
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.